RIV3

Sanofi Pasteur, a Sanofi Company · Phase 2 active Biologic

At a glance

Generic name	RIV3
Sponsor	Sanofi Pasteur, a Sanofi Company
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RIV3 CI brief — competitive landscape report
RIV3 updates RSS · CI watch RSS
Sanofi Pasteur, a Sanofi Company portfolio CI